Baixinghua AI Secures Multi-Million Yuan Angel Funding from FOHO Innovation Hub, Files for IPO

China’s natural sciences sector has witnessed rapid development in recent decades, with scientific achievements in physics, biology, chemistry, and medicine gradually gaining prominence on the global stage.

More scientific research is rapidly advancing in China, while the massive surge in pharmaceutical SCI databases and open-source clinical databases is posing increasing challenges for researchers in data analysis and literature review. Currently, the compound annual growth rate of publicly available medical data and scientific papers has exceeded 70% over the past three years.

Given the differing formats and standards across multimodal medical data, efficient tools capable of rapidly and accurately analyzing and deriving insights from massive volumes of research data are widely anticipated by researchers in China.

AI’s distinct advantages in data retrieval, logical filtering, and precision-driven efficiency, coupled with its strong performance across various fields, make it the ideal choice for addressing this current situation.

According to VCBeat, AI data retrieval platform BaiXingHua AI recently completed an angel financing round worth several million yuan, exclusively invested by Fenhu International Innovation Center. The funds raised will be used for the development of its own AI platform, team expansion, and market outreach.

White Star Flower AI was established in Zhongguancun, Beijing on September 24, 2020., founded by two veterans with extensive practical experience in AI algorithm technology for the pharmaceutical and medical industries.Wang Suhong, Co-founder & CEO of Baixinghua AISecured first place in multiple international pharmaceutical algorithm competitions and previously worked on AI for many years at the Second Academy of China Aerospace Science and Industry Corporation.Xiao Zhifeng, Co-Founder & CTOHe is an Associate Professor of Computer Science at a university in Pennsylvania, USA, and has participated in several large-scale research collaboration projects with domestically listed pharmaceutical companies over the past two years. Both individuals possess extensive experience in AI algorithms for the pharmaceutical industry.

From manually reviewing hundreds of scientific research papers,To leverage the BAIX analytics platform to simultaneously analyze 40 million SCI papers，White Star Flower AI aims to increase the work efficiency of pharmaceutical research by 50%.。

BAIX Pharmaceutical AI PlatformDatabase with over 1 million real-world/clinical data records，A Knowledge Graph Integrating Over 14 Million SCI Medical Literature Records, a comprehensive medical knowledge graph can extract key information from sources such as SCI data, hospital data, and clinical databases to establish nodes and generate relationships by defining various relationship types.

Moreover, the platform also possesses years of accumulated12PB Gene Drug/3D Database, providing users with services such as medical data statistics download, exploration of new indications, and prediction of clinical trial results. Meanwhile, the platform can also quantify and analyze large volumes of publicly available clinical datasets and drug-gene datasets, offering more precise data support for scientists conducting basic and clinical medical research.

Overall, the BAIX Medical AI Platform not only enables information retrieval and visual presentation for large-scale, highly complex datasets but also leverages its proprietary database to calculate relationships among diseases, targets, and drugs, supporting applications in drug development, indication expansion, and clinical trials.

Wang Suhong, Co-founder & CEO of Bai Xing Hua AIstated: “We extend our sincere gratitude to the Fenhu International Innovation Center for its support and recognition. The exponential growth of medical and pharmaceutical data has rendered existing analytical tools and software inadequate for delivering accurate insights. There is an urgent market need for a platform that enables scientists and pharmaceutical enterprises to conduct more extensive, in-depth, and precise data analysis. By integrating precisely annotated map data from nearly 40 million SCI-indexed publications with proprietary algorithmic models that fuse various open-source medical and pharmacogenomic databases, Baixinghua AI’s BAIX platform provides scientists and innovative drug developers with superior algorithmic research tools, thereby accelerating scientific research and pharmaceutical R&D.”

Alex, Investment Partner at the Fenhu International Innovation Center (FOHO Innovation Hub)He stated, “In recent years, we have witnessed numerous successful applications of artificial intelligence (AI) technologies in the biopharmaceutical sector. AI has also played a pivotal role in breaking down data silos and unlocking the value of pharmaceutical data. Bai Xinghua’s team and technology are addressing a critical challenge in the life sciences field. They empower frontline researchers, pharmaceutical companies, and clinicians to more efficiently extract key actionable insights from vast oceans of scientific data, thereby shortening R&D cycles, reducing costs, and accelerating innovation at the forefront of life sciences.”

Fenhu International Innovation Center (FOHO Innovation Hub) is an innovation incubator established by C2C Startups, a global innovation incubation and acceleration platform, in the Yangtze River Delta Eco-Green Integrated Development Demonstration Zone. It continuously focuses on frontier technological innovations in deep tech, big health and life sciences, and carbon neutrality. Committed to identifying technology entrepreneurs with a global vision, entrepreneurial spirit, and foresight, it provides comprehensive support ranging from early-stage incubation and investment to long-term companionship, thereby empowering the global development of Chinese sci-tech enterprises.